CMS proposes rules to improve Medicaid drug price transparency
(By Rylee Wilson for Becker’s Hospital Review)
CMS is proposing a set of rules for drug manufacturers, pharmaceutical benefit managers and managed care plans to increase drug price transparency in Medicaid.
In a proposed rule published May 23, the agency laid out plans to increase transparency by requiring manufacturers to disclose some pricing information through a price survey and requiring PBMs to disclose more pricing details to managed care plans. Continue reading here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org